Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE study of atezolizumab + derazantinib in FGFR2-rearranged intrahepatic cholangiocarcinoma
2020-004938-38Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and derazantinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate within 9 months. Started Aug 2021; status: active.
02
Drugs
atezolizumabderazantinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2020-004938-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004938-38.